Emerald Mutual Fund Advisers Trust’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-120,505
| Closed | -$2.77M | – | 206 |
|
|
2025
Q4 | $2.77M | Sell |
120,505
-122,297
| -50% | -$4.02M | 0.14% | 118 |
|
|
2025
Q3 | $7.3M | Sell |
242,802
-52,515
| -18% | -$1.57M | 0.38% | 97 |
|
|
2025
Q2 | $10.7M | Sell |
295,317
-45,658
| -13% | -$1.65M | 0.65% | 59 |
|
|
2025
Q1 | $12.3M | Buy |
340,975
+16,538
| +5% | +$688K | 0.88% | 43 |
|
|
2024
Q4 | $13.6M | Sell |
324,437
-104,865
| -24% | -$5.2M | 0.83% | 48 |
|
|
2024
Q3 | $23.8M | Buy |
429,302
+38,778
| +10% | +$1.98M | 1.24% | 28 |
|
|
2024
Q2 | $16.1M | Buy |
390,524
+5,184
| +1% | +$221K | 0.84% | 48 |
|
|
2024
Q1 | $18M | Hold |
385,340
| – | – | 0.94% | 41 |
|
|
2023
Q4 | $18.4M | Sell |
385,340
-1,983
| -0.5% | -$76.9K | 0.98% | 39 |
|
|
2023
Q3 | $13.8M | Sell |
387,323
-52,818
| -12% | -$2.09M | 0.83% | 51 |
|
|
2023
Q2 | $20.3M | Buy |
440,141
+51,613
| +13% | +$2.39M | 1.1% | 32 |
|
|
2023
Q1 | $15.6M | Buy |
388,528
+135,676
| +54% | +$5.82M | 0.92% | 42 |
|
|
2022
Q4 | $11.7M | Buy |
252,852
+14,648
| +6% | +$576K | 0.73% | 59 |
|
|
2022
Q3 | $9.86M | Buy |
238,204
+71,866
| +43% | +$3.69M | 0.62% | 66 |
|
|
2022
Q2 | $9.92M | Sell |
166,338
-15,866
| -9% | -$976K | 0.58% | 72 |
|
|
2022
Q1 | $13.2M | Sell |
182,204
-58,565
| -24% | -$4.07M | 0.58% | 68 |
|
|
2021
Q4 | $20.2M | Buy |
240,769
+138,892
| +136% | +$11.3M | 0.71% | 56 |
|
|
2021
Q3 | $9.19M | Sell |
101,877
-122,205
| -55% | -$11M | 0.32% | 97 |
|
|
2021
Q2 | $21.4M | Sell |
224,082
-14,941
| -6% | -$1.56M | 0.7% | 57 |
|
|
2021
Q1 | $27.2M | Buy |
239,023
+20,633
| +9% | +$2.81M | 0.9% | 34 |
|
|
2020
Q4 | $30.2M | Buy |
+218,390
| New | +$25.9M | 1.05% | 27 |
|
|
2017
Q1 | – | Sell |
-264,546
| Closed | -$18.6M | – | 283 |
|
|
2016
Q4 | $18.6M | Hold |
264,546
| – | – | 0.89% | 37 |
|
|
2016
Q3 | $18.8M | Buy |
+264,546
| New | +$16.9M | 0.96% | 27 |
|
|
2015
Q3 | – | Sell |
-52,305
| Closed | -$5.36M | – | 286 |
|
|
2015
Q2 | $5.36M | Sell |
52,305
-9,020
| -15% | -$700K | 0.41% | 91 |
|
|
2015
Q1 | $3.65M | Sell |
61,325
-31,780
| -34% | -$1.77M | 0.3% | 101 |
|
|
2014
Q4 | $4.08M | Buy |
93,105
+51,259
| +122% | +$2.35M | 0.35% | 91 |
|
|
2014
Q3 | $2.37M | Buy |
41,846
+7,112
| +20% | +$358K | 0.23% | 119 |
|
|
2014
Q2 | $1.56M | Buy |
34,734
+12,204
| +54% | +$502K | 0.14% | 137 |
|
|
2014
Q1 | $1.1M | Buy |
+22,530
| New | +$1.16M | 0.11% | 151 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
Emerald Mutual Fund Advisers Trust's RARE Position: Q1 2026 in Review
Emerald Mutual Fund Advisers Trust sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 120,505 shares — an estimated $2.77M sold.
Emerald Mutual Fund Advisers Trust first reported a position in RARE in Q1 2014 and held it in 29 quarters. The position peaked at $30.2M in Q4 2020. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- Emerald Mutual Fund Advisers Trust reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
- Emerald Mutual Fund Advisers Trust sold 120,505 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $2.77M.
- Emerald Mutual Fund Advisers Trust first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 29 quarters.
- Emerald Mutual Fund Advisers Trust's Ultragenyx Pharmaceutical position peaked at $30.2M in Q4 2020.
- 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q1 2026, filed 4 May 2026.